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 Context.—Metastatic metaplastic breast carcinoma
(MPBC) is an uncommon, but aggressive, tumor resistant
to conventional chemotherapy.
Objective.—To learn whether next-generation sequenc-
ing could identify potential targets of therapy for patients
with relapsed and metastatic MPBC.
Design.—Hybridization capture of 3769 exons from 236
cancer-related genes and 47 introns of 19 genes commonly
rearranged in cancer was applied to a minimum of 50 ng of
DNA extracted from 20 MPBC formalin-fixed, paraffin-
embedded specimens and sequenced to high uniform
coverage.
Results.—The 20 patients with MPBC had a median age
of 62 years (range, 42–86 years). There were 9 squamous
(45%), 9 chondroid (45%), and 2 spindle cell (10%)
MPBCs, all of which were high grade. Ninety-three
genomic alterations were identified, (range, 1–11) with
19 of the 20 cases (95%) harboring an alteration that could
potentially lead to a targeted treatment option. The most-
common alterations were in TP53 (n¼ 69; 75%), PIK3CA
(n¼ 37; 40%), MYC (n¼ 28; 30%), MLL2 (n¼ 28; 30%),
PTEN (n¼23; 25%), CDKN2A/B (n¼19; 20%), CCND3 (n
¼ 14; 15%), CCNE1 (n¼ 9; 10%), EGFR (n¼ 9; 10%), and
KDM6A (n ¼ 9; 10%); AKT3, CCND1, CCND2, CDK4,
FBXW7, FGFR1, HRAS, NF1, PIK3R1, and SRC were each
altered in a single case. All 16 MPBCs (100%) that were
negative for ERBB2 (HER2) overexpression by immunohis-
tochemistry and/or ERBB2 (HER2) amplification by fluo-
rescence in situ hybridization were also uniformly (100%)
negative for ERBB2 amplification by next-generation
sequencing–based copy-number assessment.
Conclusions.—Our results indicate that genomic profil-
ing using next-generation sequencing can identify clinical-
ly meaningful alterations that have the potential to guide
targeted treatment decisions in most patients with meta-
static MPBC.
(Arch Pathol Lab Med. 2015;139:642–649; doi: 10.5858/
arpa.2014-0200-OA)
Metaplastic carcinoma of the breast (MPBC) is anuncommon, malignant tumor with a variable histo-
logic appearance that differs substantially from classic
invasive ductal adenocarcinoma and invasive lobular ade-
nocarcinoma.1–5 Metaplastic carcinoma of the breast typi-
cally presents at a more-advanced stage than either invasive
ductal or lobular adenocarcinoma cases and, in general, has
a worse prognosis.6,7 On routine biomarker testing for
estrogen receptor (ER) and/or progesterone receptor (PR)
status, most MPBCs are negative.8 Similarly, virtually all
MPBC cases are negative for HER2 overexpression and
amplification by either immunohistochemistry (IHC) and/or
fluorescence in situ hybridization.8,9 These findings com-
bined with messenger RNA (mRNA) profiling studies
indicate that most MPBCs are so-called triple-negative
breast cancers (TNBCs) that cluster with the basaloid-
phenotype cancers in the breast cancer molecular-portraits
system.10–12 However, although the TNBC and basaloid
types of breast cancer are classically associated with
responsiveness to cytotoxic chemotherapy,13,14 metastatic
MPBC is generally regarded as a chemoresistant, highly
aggressive form of the disease.15,16 Given the poor prognosis
and reduced response to treatment for MPBC, this study
was performed to evaluate potential, targeted treatment
opportunities for patients with MPBC.
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MATERIALS AND METHODS
Hybridization capture of 3769 exons from 236 cancer-related
genes and 47 introns of 19 genes commonly rearranged in cancer
was applied to a minimum of 50 ng of DNA extracted from 20
formalin-fixed, paraffin-embedded cases of relapsed and metastatic
MPBC that had previously been treated with systemic therapies.17
There were no early stage or untreated MPBC cases included in this
study. The 20 cases represented all (100%) of the MPBC samples
received at Foundation Medicine, Inc (Cambridge, Massachusetts),
for next-generation sequencing between January 1, 2013, and
February 1, 2014. The 20 MPBC samples were sequenced to high,
uniform coverage (average 3833, with .99% of exons covered at
greater than 3100). All MPBC cases were reviewed by 2
pathologists (J.S.R. and S.B.) and were subdivided into histologic
subtypes: predominantly spindle cell (sarcomatoid), predominantly
squamous, predominantly chondroid, and mixed. Formalin-fixed,
paraffin-embedded specimens were sequenced to high (average
3833), uniform coverage, as previously described.17 Genomic
alterations (base substitutions, small insertions/deletions [indels],
select rearrangements, and copy-number alterations) were deter-
mined. Potentially actionable alterations were defined as those linked
to anticancer drugs on the market or in registered clinical trials.
Local site permissions to use clinical samples and their accompa-
nying medical records and pathology reports were used for this
study. No additional research was performed on the tumor samples
beyond the DNA sequencing.
RESULTS
The 20 patients with MPBC had a median age of 62 years
(range, 42–86 years). There were 9 predominantly squamous
(45%), 9 predominantly chondroid (45%), and 2 predom-
inantly spindle cell (sarcomatoid) (10%) MPBCs, all of
which were originally diagnosed as high-grade tumors
(Table 1). All MPBCs (20 of 20; 100%) had pure MPBC
histology, and none of the cases (0 of 20; 0%) in this series
had foci of either classic invasive ductal carcinoma or
invasive lobular carcinoma admixed with the metaplastic
carcinoma areas. All of the MPBCs (20 of 20; 100%) were
advanced stage: 1 MPBC (5%) was stage II, 2 (10%) were
stage III, and 17 (85%) were stage IV. Because this study
included only patients with relapsed and metastatic disease,
there were no well-differentiated or stage-I tumors included
in this patient cohort. Of the 16 cases (80%) with available
biomarker results, 6% (n ¼ 1) were ERþ, 12% (n ¼ 2) were
PRþ, and 100% (n ¼ 16) were HER2 by either IHC or
fluorescence in situ hybridization testing. Thus, 87% of the
MPBCs were TNBC and 13% were either ERþ or PRþ
positive. The targeted next-generation sequencing assay
used in this study identified 93 genomic alterations in the 20
MPBC, with at least one alteration identified in all cases
(mean [SD], 4.65 [2.08] per tumor). Nineteen (95%) of the
20 MPBC cases harbored 36 alterations that could poten-
tially lead to a targeted therapeutic treatment option (mean
[SD], 1.8 [1.08] per tumor).18,19 The most-common, biolog-
ically relevant alterations were alterations in TP53 (n ¼ 15;
75%), MYC (n¼6; 30%), MLL2 (n¼6; 30%), and KDM6A (n
¼ 2; 10%). The most-common, potentially targetable
alterations were mutations, amplifications, and homozygous
deletions of PIK3CA (n ¼ 8; 40%), PTEN (n ¼ 5; 25%),
CDKN2A/B (n¼ 4; 20%), CCND3 (n¼ 3; 15%), CCNE1 (n¼
2; 10%), and EGFR (n ¼ 2; 10%), with AKT3, CCND1,
CCND2, CDK4, FBXW7, FGFR1, HRAS, NF1, PIK3R1, and
SRC altered in a single case (Figure 1; Table 1). The
actionable alterations discovered in the MPBC have
potential for a variety of targeted therapies, including
inhibitors of mTOR, cyclin-dependent kinase inhibitors,
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MEK, EGFR, FGFR1, and SRC. The results of routine HER2
testing were available for 16 patients (80%) with MPBC and
all (100%) were negative for HER2 overexpression, as
determined by IHC and/or negative for HER2 amplification
as determined by fluorescence in situ hybridization at
outside laboratories. All 16 (100%) of those cases were also
negative for ERBB2 copy-number gain (amplification) by the
next-generation sequencing assay.
COMMENT
Molecular studies of MPBC to date have predominantly
used IHC, fluorescence in situ hybridization, and mRNA
transcriptional profiling techniques and have demonstrated
that MPBC clusters with the TNBC/basaloid pheno-
types.20–22 Metaplastic carcinomas of the breast have further
been associated with the so-called claudin-low subtype of
the basaloid phenotype in the molecular-portraits system.23
In addition, mRNA profiling has linked the various
histologic appearances of MPBC to various expression of a
diverse group of genes.24–25 Studies26 of TP53 have
demonstrated that TP53 mutation is present in both the
epithelial and mesenchymal components in MPBC with
mixed histologies at a similar frequency (~75%). In the
current study, the 20 MPBCs showed a histologically
uniform pattern in that none of the tumors featured a
mixture of differentiated invasive ductal adenocarcinoma
with metaplastic spindle cell (sarcomatoid), squamous, or
chondroid foci. Although the numbers of cases in each
category is small, we identified no specific pattern of altered
cancer genes that were associated with the sarcomatoid
(spindle cell), squamous, or chondroid histologic subtypes.
Similarly, when the MPBC cases are categorized into pure
epithelial (0 cases; 0%), pure mesenchymal (7 cases; 35%),
and mixed epithelial and mesenchymal (13 cases; 65%)
groups, no significant differences in the genomic alterations
between groups was observed. Instead, similar to prior
profiling studies, we identified a heterogeneous combina-
tion of alterations, yielding a relatively unique mutation
profile for each tumor despite apparent histologic similar-
ities. Additionally, the current study also confirms 2
noteworthy findings from previously published MPBC
transcriptional profiling studies: EGFR amplification in the
absence of EGFR mutations27–28 and alterations in the Wnt
signaling pathway without mutations in CTNNB1.29–31
Given the histologic picture of MPBC with various types
of mesenchymal differentiation, including the spindle cell
Figure 1. Tile plot of genomic alterations detected by genomic profiling of 20 cases of advanced-stage metaplastic breast carcinoma.
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(sarcomatoid) and chondroid variants of the disease, there
has been significant interest in studying genes and biologic
pathways associated with the epithelial to mesenchymal
transition and the cancer stem cell hypothesis32–37 in MPBC.
Previous studies using IHC or mRNA profiling of MPBC
have identified altered expression levels of epithelial to
mesenchymal transition genes or directly related pathways.
In particular, altered expression of SNAIL, a transcriptional
repressor of E-cadherin (CDH1), has been proposed as an
important epithelial-mesenchymal transition pathway gene
associated with recurrence and metastasis in the disease,
especially in the chondroid variant of MPBC.38–40 However,
in this study, sequence alterations or copy-number gains or
losses of these epithelial-mesenchymal transition-associated
genes were not identified. In particular, no mutations or
homozygous deletions of CDH1 were identified in this
study.
The disease-free and overall survival results for patients
with MPBC is significantly shorter than that for non-MPBC
treated with cytotoxic agents in either the metastatic or the
neoadjuvant settings.12–14 Nineteen of the 20 MPBC cases
(95%) in this series harbored 36 alterations that could
potentially lead to a targeted, therapeutic treatment option
(mean [SD], 1.8 [1.06] per tumor). This result is similar to a
series41 of 273 routine (non-MPBC) breast cancers evaluated
using the same assay, where 246 (90%) harbored at least
one potentially actionable alteration. The clinically mean-
ingful alterations that could conceivably guide targeted
treatment decisions were identified in 19 of 20 (95%) of the
patients in multiple, biologic pathways (Table 2). Cell-cycle
alterations were common, including homozygous deletion
of CDKN2A in 4 (20%) and amplifications of CCND3,
CCNE1, CCND1, CCND2, and CDK4 in 8 (40%) of the
MPBC cases, a subset of which may indicate the potential
for use of cell-cycle inhibitors. An example is case B07, a
chest wall relapse of a MPBC in a 61-year-old woman
whose tumor demonstrated amplification of CDK4 (17
copies), in addition to amplification of MYC (9 copies) and
the R248Q base substitution in TP53 (Figure 2, A through
C). CDK4 amplification has been reported42 in 1.5% to 15%
of breast carcinomas and expression has been correlated
with amplification. Recent results43–46 focused on targeting
cell-cycle regulatory genes in clinical trials for patients with
cancer, and alterations in those cell growth regulatory
pathways are showing significant promise.
PIK3CA mutations are important genomic alterations in
the pathogenesis and progression of breast cancer.47–49
PIK3CA mutations were identified in 8 (40%) of the patients
with MPBC in the current study (Figure 3, A and B), which is
consistent with a previous study35 that demonstrated
PIK3CA mutations in 9 of 19 MPBCs (48%). The PIK3CA
mutation frequency in MPBC thus appears to be greater
than the 25% frequency listed for all types of breast cancer50
and for TNBCs as a group.51 PIK3CA mutations have been
linked to improved outcomes in breast cancer.52 The PI3K
pathway is now widely considered a target of therapy for
cancer in general53 and for breast cancer, in particular.54
Moreover, activating mutations in PIK3CA predict sensitivity
to inhibitors of PI3K or its downstream signaling pathway
(the PI3K/AKT/mTOR pathway).55 The mTOR inhibitor
everolimus has been approved for use in hormone
receptor–positive, HER2, advanced breast cancer, in
combination with exemestane, and clinical trials with other
mTOR inhibitors continue in breast cancer.56 PTEN (phos-
Table 2. Significant Targetable Genomic Alterations Discovered by Next-Generation Sequencing Assessment
of 20 Cases of Advanced-Stage Metaplastic Breast Carcinoma (MPBC)
Gene (%)
Genomic Alterations
Total Targetable
Genomic Alterations,
No.
Potential,
Targeted
Therapeutic
Loss/Homozygous
Deletion,
No.
Base
Substitution,
No.
Truncation,
No.
Amplification,
No.
PIK3CA (40) 8 8 Everolimus
Temsirolimus
PTEN (25) 3 2 5 Everolimus
Temsirolimus
CDKN2A/B (20) 4 4 CDK 4/6 inhibitors
CCND3 (15) 3 3 Nutlins
CCNE1 (10) 2 2 Nutlins
EGFR (10) 2 2 Erlotinib
Afatinib
Gefitinib
HRAS (5) 1 1 Trametinib
AKT3 (5) 1 1 Everolimus
Temsirolimus
CCND1 (5) 1 1 Nutlins
CCND2, (5) 1 1 Nulins
CDK4 (5) 1 1 CDK 4/6 inhibitors
FBXW7 (5) 1 1 Everolimus
Temsirolimus
FGFR1 (5) 1 1 Pazopanib
Ponatinib
Regorafenib
NF1 (5) 1 1 Everolimus
Temsirolimus
PI3KR1 (5) 1 1 Everolimus
Temsirolimus
SRC (5) 1 1 Bosutinib
Dasatinib
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phatase and tensin homolog) functions as a tumor
suppressor by negatively regulating the PI3K/Akt/mTOR
pathway.57 Mutations in PTEN have been reported50 in 5%
of breast cancers but have not been previously analyzed, to
our knowledge, specifically in metaplastic breast carcinoma.
In this study, 5 of the 20 MPBC cases (25%) harbored PTEN
alterations, including 3 homozygous deletions and 2
truncating mutations, which could potentially benefit from
PI3K inhibitors in at least a subset of these typically difficult-
to-treat breast cancers.
In summary, MPBC is a rare, aggressive subtype of breast
cancer, which remains a significant clinical problem given
the high propensity to present at advanced stages and
progress rapidly in a chemoresistant fashion. This study
identified at least one clinically meaningful alteration that
could potentially lead to a targeted treatment option in most
patients. However, the future effect of the cost of the next-
generation sequencing testing and potential use of targeting
agents for metastatic MPBC must be weighed against the
potential for increasing disease-free and overall survival in
this disease. Moreover, the further development of person-
alized oncology for MPBC and all types of breast cancer will
require the continued development of mechanisms driven
clinical trials, such as the emerging umbrella and basket
trials, which are based on the use of biomarkers to select
patients for both single-agent and multiagent, novel
treatments. Given the poor prognosis and limited treatment
options for patients with metastatic MPBC, genomic
profiling using next-generation sequencing has the potential
to identify new treatment paradigms and to fulfill an unmet
clinical need in this disease.
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